Log in

NASDAQ:LOGCLogicBio Therapeutics Stock Price, Forecast & News

$6.85
+0.05 (+0.74 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.75
Now: $6.85
$6.85
50-Day Range
$4.25
MA: $5.74
$7.35
52-Week Range
$3.05
Now: $6.85
$20.07
Volume16,185 shs
Average Volume54,954 shs
Market Capitalization$159.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.55
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LOGC
CUSIPN/A
CIKN/A
Phone617-245-0399

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.84 per share

Profitability

Net Income$-40,130,000.00

Miscellaneous

Employees23
Market Cap$159.74 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive LOGC News and Ratings via Email

Sign-up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter.

LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

How has LogicBio Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

LogicBio Therapeutics' stock was trading at $7.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, LOGC shares have decreased by 2.7% and is now trading at $6.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of LogicBio Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for LogicBio Therapeutics.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for LogicBio Therapeutics.

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics Inc (NASDAQ:LOGC) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.07. The company had revenue of $1.02 million for the quarter. View LogicBio Therapeutics' earnings history.

What price target have analysts set for LOGC?

2 analysts have issued 1 year price targets for LogicBio Therapeutics' shares. Their forecasts range from $20.00 to $20.00. On average, they expect LogicBio Therapeutics' share price to reach $20.00 in the next twelve months. This suggests a possible upside of 192.0% from the stock's current price. View analysts' price targets for LogicBio Therapeutics.

What are Wall Street analysts saying about LogicBio Therapeutics stock?

Here are some recent quotes from research analysts about LogicBio Therapeutics stock:
  • 1. According to Zacks Investment Research, "LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company's technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. " (11/14/2019)
  • 2. Chardan Capital analysts commented, "We see limited read-across on nuclease-free editing controversy On 21 July, researchers from the California posted a manuscript to the bioRxiv preprint server outlining outlining unsuccessful efforts to reproduce efficient nuclease-free genome editing with clade F AAV vectors, based on a 2018 publication from Homology Medicines (unrated), which reported >50% editing with similar AAV vectors isolated from hematopoietic stem cells (AAVHSCs). Increasing attention drawn to the preprint to us may have sent Homology’s share price down >20% by the market close on July 25th. Below, we highlight some considerations for interpreting the data and the extent of potential read-across for other companies in the space." (7/29/2019)

Has LogicBio Therapeutics been receiving favorable news coverage?

News coverage about LOGC stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. LogicBio Therapeutics earned a coverage optimism score of 1.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutLogicBio Therapeutics.

Are investors shorting LogicBio Therapeutics?

LogicBio Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 212,400 shares, an increase of 8.9% from the March 31st total of 195,000 shares. Based on an average daily volume of 88,700 shares, the days-to-cover ratio is currently 2.4 days. Approximately 1.5% of the company's shares are sold short. View LogicBio Therapeutics' Current Options Chain.

Who are some of LogicBio Therapeutics' key competitors?

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Acceleron Pharma (XLRN), Alector (ALEC), Gossamer Bio (GOSS), Crispr Therapeutics (CRSP), Kaleido Biosciences (KLDO), Stoke Therapeutics (STOK), Tcr2 Therapeutics (TCRR), AbbVie (ABBV) and Akero Therapeutics (AKRO).

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the following people:
  • Mr. Frederic Chereau, Pres, CEO & Director (Age 52)
  • Mr. Matthias B. Jaffé, Chief Financial Officer (Age 50)
  • Mr. Tom Wilton, Chief Bus. Officer (Age 45)
  • Dr. Leszek Lisowski Ph.D., Co-Founder
  • Dr. Adi Barzel, Co-Founder

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an IPO on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

Who are LogicBio Therapeutics' major shareholders?

LogicBio Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Samlyn Capital LLC (3.42%), BlackRock Inc. (2.17%), JPMorgan Chase & Co. (1.75%), Geode Capital Management LLC (0.44%), First Trust Advisors LP (0.05%) and IHT Wealth Management LLC (0.05%). View institutional ownership trends for LogicBio Therapeutics.

Which major investors are selling LogicBio Therapeutics stock?

LOGC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and First Trust Advisors LP. View insider buying and selling activity for LogicBio Therapeutics.

Which major investors are buying LogicBio Therapeutics stock?

LOGC stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Samlyn Capital LLC, IHT Wealth Management LLC, Geode Capital Management LLC, Victory Capital Management Inc., and Victory Capital Management Inc.. View insider buying and selling activity for LogicBio Therapeutics.

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $6.85.

How big of a company is LogicBio Therapeutics?

LogicBio Therapeutics has a market capitalization of $159.74 million. The company earns $-40,130,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. LogicBio Therapeutics employs 23 workers across the globe.

What is LogicBio Therapeutics' official website?

The official website for LogicBio Therapeutics is www.logicbio.com.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at 617-245-0399 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.